IRulya Therapeutics Inc. cash flow to debt ratio of -224.27% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

IRulya Therapeutics Inc.'s free cash flow has decreased 29.90% from $-32.16M last year to $-41.78M, signaling decreasing performance

IRulya Therapeutics Inc. has insufficient data to evaluate this check.

IRulya Therapeutics Inc. has insufficient data to evaluate this check.

IRulya Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable

IRulya Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

IRulya Therapeutics Inc. has insufficient data to evaluate this check.

IRulya Therapeutics Inc. has insufficient data to evaluate this check.

IRulya Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

IRulya Therapeutics Inc.'s return on equity of -413.28%, is lower than 15.00%, indicating bad performance

IRulya Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

IRulya Therapeutics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

IRulya Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

IRulya Therapeutics Inc. has negative free cash flow, indicating cash burn

IRulya Therapeutics Inc.'s yearly earnings has decreased 47.78% since last year from $-56.83M to $-83.98M, signaling decreasing performance

IRulya Therapeutics Inc. has insufficient data to evaluate this check.

ROIC -104.64% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

IRulya Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

IRulya Therapeutics Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

IRulya Therapeutics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

IRulya Therapeutics Inc. has insufficient data to evaluate this check.

IRulya Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

IRulya Therapeutics Inc. has insufficient data to evaluate this check.

IRulya Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

IRulya Therapeutics Inc. has insufficient data to evaluate this check.

IRulya Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

IRulya Therapeutics Inc. has a price-to-book ratio of 1.81x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

IRulya Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue